Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

BridgeBio Pharma Net Worth 2018-2024 | BBIO

Interactive chart of historical net worth (market cap) for BridgeBio Pharma (BBIO) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. BridgeBio Pharma net worth as of January 23, 2025 is $6.77B.
  
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $6.773B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $24.935B 8.18
Dr Reddy's Laboratories (RDY) India $12.596B 24.10
Bausch Health Cos (BHC) Canada $2.792B 2.06
Supernus Pharmaceuticals (SUPN) United States $2.108B 28.70
Amphastar Pharmaceuticals (AMPH) United States $1.738B 10.44
Personalis (PSNL) United States $0.396B 0.00
Taysha Gene Therapies (TSHA) United States $0.314B 21.86
Assembly Biosciences (ASMB) United States $0.095B 0.00
Sol-Gel Technologies (SLGL) Israel $0.025B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00